Search
Cobalt
go.drugbank.com/drugs/DB14574ApprovedWithdrawnIt is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.
Avexitide
go.drugbank.com/drugs/DB14806ApprovedInvestigationalWithdrawnAvexitide is under investigation in clinical trial NCT02996812 (Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia).
Bezitramide
go.drugbank.com/drugs/DB01459ApprovedIllicitWithdrawnAfter cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.
Iopentol
go.drugbank.com/drugs/DB13861ExperimentalIopentol is used as a contrast medium.
Categories: Compounds used in a research, industrial, or household settingIobenzamic acid
go.drugbank.com/drugs/DB13428ExperimentalCategories: Compounds used in a research, industrial, or household settingIoglycamic acid
go.drugbank.com/drugs/DB13741ExperimentalCategories: Compounds used in a research, industrial, or household settingSimendan
go.drugbank.com/drugs/DB12286ExperimentalCategories: Compounds used in a research, industrial, or household settingRecombinant SARS-CoV-2 Vaccine (Sf9 Cell)
go.drugbank.com/drugs/DB16443InvestigationalIt also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2[A226853]. … In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection[A226853].
Moschus berezovskii musk sac resin
go.drugbank.com/drugs/DB14247InvestigationalMoschus berezovskii musk sac resin is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Gotistobart
go.drugbank.com/drugs/DB19100InvestigationalGotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).